Comparator Sourcing & Procurement
How Can You Secure Reliable Comparator Supply for Global Clinical Trials?
Comparator sourcing is one of the most critical components of the clinical trial supply chain. Tanner provides strategic comparator sourcing and procurement services supporting global studies, helping sponsors and CROs mitigate shortages, manage regulatory complexity, control cost exposure, and protect study timelines.
What Makes Comparator Sourcing Challenging?
Market shortages and constrained supply
Branded comparators, legacy therapies, biosimilars, and specialty products may be limited, market-restricted, or subject to sudden allocation changes, making early planning critical.
-
We address this through early engagement and early sourcing strategy, supported by global sourcing capability and qualified supplier networks governed by a global QMS.
Inconsistent or Incomplete Documentation
Documentation gaps can delay QP release, packaging and labeling, and site distribution, making incomplete records a common cause of clinical trial supply delays.
-
We address this through supplier governance and documentation control, integrated across the clinical trial supply chain and supported by Chain of Custody oversight.
Regulatory Variability Across Regions
Governed by differing national regulations, import/export constraints, and GDP and broader GxP requirements that vary by geography, meaning a sourcing strategy effective in one country may not translate to another.
-
We manage this through global sourcing capability and qualified supplier networks governed by a global QMS, supported by early engagement to align sourcing strategy with regional requirements.
Protocol Complexity & Late Changes
Adaptive designs, new cohorts, dosing changes, or geographic expansion can trigger sudden increases in demand, new sourcing requirements and urgent resupply needs, amplifying risk if sourcing strategies are not already in place.
-
We manage this through early engagement, proactive forecasting, and lifecycle planning, integrating comparator sourcing within the clinical trial supply chain to support evolving supply requirements.
Parallel Trade & Supply Integrity Risk
Products sourced through parallel markets can introduce traceability gaps, variability in packaging and labeling and increased audit exposure, putting Chain of Custody and study integrity at risk.
-
We address this through supplier governance, documentation control, and qualified supplier networks governed by a global QMS, with structured oversight of Chain of Custody across the clinical trial supply chain.
Why Early Engagement Matters
Comparator sourcing issues rarely occur in isolation. They can cascade across the clinical trial supply chain, impacting timelines, cost control, compliance exposure and overall study continuity.
Our Capabilities
Sourcing Strategy & Global Access
-
Reliable access to branded and generic comparator products, RLDs, biosimilars, ancillary supplies, and medical devices sourced globally to support protocol requirements and regional needs.
-
Early feasibility assessments and sourcing strategies aligned to study design, enrollment projections, timelines, and geographic scope.
Procurement & Supplier Governance
-
Procurement execution across multiple markets to support both regional and global clinical trials.
-
Identification, qualification, and ongoing management of suppliers governed by Tanner’s global Quality Management System.
Documentation & Risk Management
-
End-to-end documentation management, including Chain of Custody controls and required regulatory certificates, supporting audit readiness and regulatory compliance in clinical trials.
-
Integrated forecasting and proactive resupply planning from study start through closeout, with structured strategies for constrained or limited-availability products designed to protect study timelines and maintain supply continuity.
How We Deliver Clinical Trial Solutions
Explore real-world examples of how we navigate regulatory, geographic and supply complexities to deliver compliant, global access to essential therapies.